Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.1016/S1470-2045(13)70412-1

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.